CABA vs. IVA, ABEO, GOSS, RNAC, OCGN, NGNE, PVLA, ADCT, FHTX, and TKNO
Should you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include Inventiva (IVA), Abeona Therapeutics (ABEO), Gossamer Bio (GOSS), Cartesian Therapeutics (RNAC), Ocugen (OCGN), Neurogene (NGNE), Palvella Therapeutics (PVLA), ADC Therapeutics (ADCT), Foghorn Therapeutics (FHTX), and Alpha Teknova (TKNO). These companies are all part of the "pharmaceutical products" industry.
Cabaletta Bio vs. Its Competitors
Cabaletta Bio (NASDAQ:CABA) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.
In the previous week, Inventiva had 4 more articles in the media than Cabaletta Bio. MarketBeat recorded 4 mentions for Inventiva and 0 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.00 equaled Inventiva'saverage media sentiment score.
19.1% of Inventiva shares are held by institutional investors. 11.3% of Cabaletta Bio shares are held by insiders. Comparatively, 32.0% of Inventiva shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Cabaletta Bio presently has a consensus price target of $14.43, suggesting a potential upside of 868.36%. Inventiva has a consensus price target of $10.40, suggesting a potential upside of 244.37%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, research analysts plainly believe Cabaletta Bio is more favorable than Inventiva.
Inventiva's return on equity of 0.00% beat Cabaletta Bio's return on equity.
Cabaletta Bio has a beta of 2.7, meaning that its stock price is 170% more volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500.
Cabaletta Bio has higher earnings, but lower revenue than Inventiva.
Summary
Cabaletta Bio and Inventiva tied by winning 6 of the 12 factors compared between the two stocks.
Get Cabaletta Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cabaletta Bio Competitors List
Related Companies and Tools
This page (NASDAQ:CABA) was last updated on 7/8/2025 by MarketBeat.com Staff
Free CABA Stock Alerts